Inhibition of Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Oxygen Sensors: Tricking the Body into Mounting Orchestrated Survival and Repair Responses

被引:136
|
作者
Rabinowitz, Michael H. [1 ]
机构
[1] Janssen Pharmaceut Res & Dev LLC, San Diego, CA 92121 USA
关键词
VHL TUMOR-SUPPRESSOR; FACTOR-I; ERYTHROPOIETIN GENE; HIF-ALPHA; CELLULAR ADAPTATION; FACTOR-1-ALPHA GENE; MUTATION ANALYSIS; STRUCTURAL BASIS; VASCULAR TUMORS; PROSTATE-CANCER;
D O I
10.1021/jm400386j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Hypoxia-inducible factor (HIF) is an oxygen-sensitive dimeric transcription factor that responds to pathophysiologically low O-2 tensions via up-regulation, which leads to an orchestrated biological response to hypoxia. The HIF prolyl hydroxylase domain (PHD) enzymes are non-heme, iron-containing dioxygenases requiring for activity both molecular oxygen and 2-oxoglutarate that, under normoxia, selectively hydroxylate proline residues of HIP, initiating proteosomal degradation of the latter. The dependence of HIF protein levels on the concentration of O-2 present, mediated by the PHD enzymes, forms the basis for one of the most significant biological sensor systems of tissue oxygenation in response to ischemic and inflammatory events. Consequently, pharmacological inhibition of PHD enzymes, leading to stabilization of HIP, may be of considerable therapeutic potential in treating conditions of tissue stress and injury. This Perspective reviews the PHDs and small molecule drug discovery efforts. A critical view of this challenging field is offered, which addresses potential concerns and highlights exciting possibilities for the future.
引用
收藏
页码:9369 / 9402
页数:34
相关论文
共 50 条
  • [41] Hypoxia-inducible Factor Prolyl-4-hydroxylase PHD2 Protein Abundance Depends on Integral Membrane Anchoring of FKBP38
    Barth, Sandra
    Edlich, Frank
    Berchner-Pfannschmidt, Utta
    Gneuss, Silke
    Jahreis, Guenther
    Hasgall, Philippe A.
    Fandrey, Joachim
    Wenger, Roland H.
    Camenisch, Gieri
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (34) : 23046 - 23058
  • [42] Downregulation of CYP1A2, CYP2B6, and CYP3A4 in Human Hepatocytes by Prolyl Hydroxylase Domain 2 Inhibitors via Hypoxia-Inducible Factor-α Stabilization
    Takano, Hiroki
    Yamaguchi, Jun-ichi
    Kato, Sota
    Hamada, Makoto
    Tada, Mika
    Endo, Hiromi
    DRUG METABOLISM AND DISPOSITION, 2021, 49 (01) : 20 - 30
  • [43] Deletion of hypoxia-inducible factor prolyl 4-hydroxylase 2 in FoxD1-lineage mesenchymal cells leads to congenital truncal alopecia
    Rosendahl, Ann-Helen
    Monnius, Mia
    Laitala, Anu
    Railo, Antti
    Miinalainen, Ilkka
    Heljasvaara, Ritva
    Maki, Joni M.
    Myllyharju, Johanna
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2022, 298 (04)
  • [44] Inhibition of Transforming Growth Factor β1/Smad3 Signaling Decreases Hypoxia-Inducible Factor-1α Protein Stability by Inducing Prolyl Hydroxylase 2 Expression in Human Periodontal Ligament Cells
    Watanabe, Teppei
    Yasue, Akihiro
    Tanaka, Eiji
    JOURNAL OF PERIODONTOLOGY, 2013, 84 (09) : 1346 - 1352
  • [45] Hydroxylase Inhibition Abrogates TNF-α-Induced Intestinal Epithelial Damage by Hypoxia-Inducible Factor-1-Dependent Repression of FADD
    Hindryckx, Pieter
    De Vos, Martine
    Jacques, Peggy
    Ferdinande, Liesbeth
    Peeters, Harald
    Olievier, Kim
    Bogaert, Sara
    Brinkman, Brigitta
    Vandenabeele, Peter
    Elewaut, Dirk
    Laukens, Debby
    JOURNAL OF IMMUNOLOGY, 2010, 185 (10) : 6306 - 6316
  • [46] Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Prolyl-Hydroxylase Inhibitors to Activate Hypoxia-Inducible Factor (HIF) as a Novel Therapeutic Approach in CKD
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 109 (01) : 24 - 31
  • [47] Hypoxia-inducible factor prolyl-4-hydroxylase-1 is a convergent point in the reciprocal negative regulation of NF-κB and p53 signaling pathways
    Ullah, Karim
    Rosendahl, Ann-Helen
    Izzi, Valerio
    Bergmann, Ulrich
    Pihlajaniemi, Taina
    Maki, Joni M.
    Myllyharju, Johanna
    SCIENTIFIC REPORTS, 2017, 7
  • [48] Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia
    Zuk, Anna
    Si, Zhihai
    Loi, Sally
    Bommegowda, Santhosh
    Hoivik, Debie
    Danthi, Sanjay
    Molnar, Gyongyi
    Csizmadia, Vilmos
    Rabinowitz, Michael
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2022, 383 (01) : 11 - 24
  • [49] The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
    Fox, Stephen B.
    Generali, Daniele
    Berruti, Alfredo
    Brizzi, Maria P.
    Campo, Leticia
    Bonardi, Simone
    Bersiga, Alessandra
    Allevi, Giovanni
    Milani, Manuela
    Aguggini, Sergio
    Mele, Teresa
    Dogliotti, Luigi
    Bottini, Alberto
    Harris, Adrian L.
    BREAST CANCER RESEARCH, 2011, 13 (01)
  • [50] Elucidation of clearance mechanism of TP0463518, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor: does a species difference in excretion routes exist between humans and animals?
    Takano, Hiroki
    Mizuno-Yasuhira, Akiko
    Yamaguchi, Jun-ichi
    Endo, Hiromi
    XENOBIOTICA, 2022, 52 (07) : 729 - 741